|
|
| Titles |
1993 Canadian Journal of Psychiatry Manerix |
| Related Item |
|
| Genre |
medicine |
| Genre |
medicines (psychiatric) |
| Identifier |
cjp1993aug_sep_oct_nov_dec10 |
| Note |
Witness the emergence of the first antidepressant of the RIMA class. MAOI 1959. TCA 1960. SRI 1989. RIMA 1992. Efficacy you expect, tolerability that may surprise you. Efficacy you expect. In all types of depression, Manerix has been shown to be as effective as TCAs. Clinical trials against SRIs also report equal efficacy. Tolerability that may surprise you. Numerous trials have demonstrated a far superior side effect profile compared to TCAs. What about SRIs? Although the data is limited, trials vs. fluvoxamine have shown an overall lower incidence of adverse events with Manerix - especially gastrointestinal effects. Safety is a priority. After 50 million patient days worldwide, it is clear that Manerix has a better margin of safety in overdose than TCAs. Patients can also take Manerix concomitantly with most other commonly prescribed drugs. For active patients. Because Manerix can elevate mood without causing sedation or agitation, it is effective in both withdrawn and anxious depressed patients. No psychomotor impairment promotes a smooth return to normal activities for young and elderly patients alike. First-line convenience. A short half-life creates a clear benefit to using Manerix as first-line therapy: the washout period is just 2 days. Out of the darkness…and into the light. Manerix the first RIMA antidepressant. Reversible Inhibitor of Monoamine-oxidase A. |
| Abstract |
Moclobemide, Roche, 4 images in succession; the first shows a bright light being blocked by a black object, and eventually, by the fourth image, the bright light is exposed as the object has been moved. A female first seen tired, then seen smiling, are also pictured. |
